1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET BY PRODUCT
5.1. Introduction
5.2. Patches
5.3. Gels and Ointments
6. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET BY APPLICATION
6.1. Introduction
6.2. Neurological Condition
6.3. Pain Management
6.4. Nicotine Cessation
6.5. Cardiovascular Disease
6.6. Others
7. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET BY END-USER
7.1. Introduction
7.2. Hospitals and Clinics
7.3. Surgical Centers
7.4. Others
8. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.2. Novartis AG
10.3. Medherant Ltd.
10.4. Toyochem Co. Ltd. (Artience)
10.5. AdhexPharma
10.6. Boehringer Ingelheim GmbH
10.7. Sparsha Pharma International Pvt Ltd.
10.8. Kindeva Drug Delivery
10.9. Hisamitsu Pharmaceutical Co., Inc.
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key Benefits for the Stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES